| Supplementary Protection Certificate (SPC) Summary | |||||||||||
| SPC No. | 2013/013 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Date of filing | 26/03/2013 | ||||||||||
| Notification of Application Published | 24/04/2013 | ||||||||||
| Status | Granted | ||||||||||
| Notification of Grant Published | 19/06/2013 | ||||||||||
| Date of Expiry of SPC | 13/11/2027 | ||||||||||
| Applicant |
AstraZeneca AB SE-151 85, Södertälje SWEDEN |
||||||||||
| Patent Number | 1506211 | ||||||||||
| Title of Invention | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | ||||||||||
| Date of Expiry of Patent | 14/05/2023 | ||||||||||
| Product Type | Medicinal Product | ||||||||||
| Product Identity | Dapagliflozin and pharaceutically acceptable salts threof | ||||||||||
| Market Authorisation | Ireland | ||||||||||
| Authorisation No | EU/1/12/795/001-010 | ||||||||||
| Authorisation Date | 12/11/2012 | ||||||||||
| Identity of Product Authorised | Forxiga - dapagliflozin | ||||||||||
| Address for Service |
FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 IRELAND |
||||||||||
| Renewal Fees |
|
||||||||||
| 04/04/2014 | Change of Proprietorship from Bristol-Myers Squibb Company, Route 206 and Province Line Road , P.O. Box 4000, Princeton NJ 08543-4000, United States of America to AstraZeneca AB, Västra Mälarehamnen 9, S-151 85 Södertälje, Sweden, by virtue of Deed of Assignment, dated 01/02/2014. | ||||||||||
| 28/04/2014 | Change of address of applicant(s) from AstraZeneca AB, Västra Mälarehamnen 9, S-151 85 Södertälje, Sweden to AstraZeneca AB, SE-151 85, Södertälje, Sweden recorded on 24/04/2014. | ||||||||||
| 23/02/2017 | The expiry date of SPC No. 2013/013 has been amended to bring it into line with the decision from the Court of Justice of the European Union in Case C-471/14. New expiry date is 13/11/2027. | ||||||||||
| 15/11/2022 | Application for an extension of the duration of Supplementary Protection Certificate No. 2013/013 filed on 14/11/2022. | ||||||||||